Chih-Ming Liang is an Associate Professor and the Director of the Graduate Institute of Health and Biotechnology Law of the Taipei Medical University. Liang received his S.J.D (Doctor of Juridical Science) degree from the University of Wisconsin-Madison Law School in 2013. Liang served as a post-doctoral researcher at the Research Institute for the Humanities and Social Sciences of the Ministry of Science and Technology of Taiwan from 2014-2015, before assuming the role as an Assistant Professor at the Taipei Medical University.

Liang’s main research areas involve health law and regulation, administrative law in risk society, and medical malpractice and patient safety. In each of these fields, Liang applies social scientific theories and methods to explore how the law evolves at its boundaries to meet the challenges of the modern risk society. Liang also has a special interest in cross-professional communication/collaboration and deliberative democracy. He is currently collaborating with scholars from legal, communication, and data science fields to examine data visualization and risk communication by governments during the Covid-19 pandemic.

CV (☜ URL)
 

Publications

Mandarin

• ^{Liang, C., Chen, S. A., Tsai, J. Y., & Lee, S. M., Risk Communication and Public Accountability during the Covid-19 Pandemic: A Thematic Analysis of Journalists’ Questions at the CECC’s Daily News briefings during the Period of Level 3 Alert, 29(1) J. Sci. & Health L. 37（2024）（梁志鳴、陳思安、蔡君宜、李韶曼，Covid-19疫情下的風險溝通與公共問責：三級警戒期間我國政府每日防疫記者會記者提問之主題分析，醫藥、科技與法律，2024年4月第29卷1期，頁37-98）。}
• ^{Liang, C., Major Questions Doctrine and the Legal Foundation for the United States Regulatory State: Historical Background, Recent Developments, and Potential Lessons, 177 Chengchi L. Rev. 275（2023）（梁志鳴，主要問題原則與美國管制國家之法理基礎－歷史背景、近期發展及可能啟示，政大法學評論，2024年6月第177期，頁275-344）。}
• ^{Liang, C., Fan, W. M., Hsu, & C. F., A Mix-Methods Analysis of Empirical Legal Studies in Taiwan: Knowledge Structure, Citation Network, and Qualitative Analysis, 33 Academia Sinica L. J. 1（2023）（梁志鳴、范蔚敏、許菁方，我國法實證研究社群的發展現況－－知識結構、引用網絡、與質性分析，中研院法學期刊，2023年9月第33期，頁1-80）。}
• ^{Liang, C., On Judicial Review in the Covid-19 Pandemic: Court as a Guardian of the Rule of Law in the State of Exception?, 49 Chung Yuan Fin. & Econ. L. Rev. 235（2022）（梁志鳴，法院作為法治例外狀態的守門人：論Covid-19防疫下的司法審查，中原財經法學2022年第49期，頁235-306）.}
• ^{Liang, C., On the Historical Development of Medical Alternative Dispute Resolution in the US: Lessons for Taiwan, 52 EurAmerica 655（2022）（梁志鳴，論美國訴訟外醫療紛爭處理之歷史發展經驗－－兼評我國現狀之反省與展望，歐美研究，2022年12月第52卷4期，頁655-725）.}
• ^{Liang, C., Should a Physician’s Success Rate of Personal Surgery be Informed: On the Duty to Disclose Physician-Specific Risk Information in Taiwan and the US, 72 Taiwan Health L. Report 42（2022）（梁志鳴，醫師個人手術成功率是否應告知說明：論我國與美國法上醫師個人風險資訊之告知義務，月旦醫事法報告，2022年10月第72期，頁42-63）.}
• ^{Liao, J. & Liang, C., The Scope of Practices and Informed Consent for Nurse Practitioners, 26 J. L. & Med. 77（2020, equal contribution authors）（廖仁鐸、梁志鳴，專科護理師執業範圍與說明義務範圍界限之探討，醫事法學，2020年12月第26卷1、2期合輯，頁77-96，共同貢獻作者）.}
• ^{Liang, C. & Chia, W., On Medical Disputes and Legal Education, in Legal Education for the Future Development of Medicine 1-25（2020）（梁志鳴、賈文宇，論醫療糾紛與法學教育，收錄於《醫療發展相對應之法學教育》，元照出版社，2020年1月，頁1-25（非匿名審查））。}
• ^{Liang, C., Theorizing Interdisciplinary Legal Application and Reasoning with Sociological Theories: The Debates between Local Custom and National Standard in the U.S. and between Medical Norm and Medical Standard in Taiwan as Examples, 24 Academia Sinica L. J. 1（2019）（梁志鳴，論跨領域法律解釋適用之原則與挑戰—慣習與全國水準之辯證及我國醫療常規與醫療水準之論戰為例，中研院法學期刊，2019年3月第24期，頁255-361）.}
• ^{Liang, C., Evaluating the Medical Adverse Event Prevention and Resolution Act from the Perspective of Patient Safety Risk Management (2), 21 Taiwan Health L. Report 137（2018）（梁志鳴，評醫療事故預防及處理法草案：以病人安全風險管理為中心（下），月旦醫事法報告，2018年7月第21期，頁137-155）.}
• ^{Liang, C., Evaluating the Medical Adverse Event Prevention and Resolution Act from the Perspective of Patient Safety Risk Management (1), 20 Taiwan Health L. Report 144（2018）（梁志鳴，評醫療事故預防及處理法草案：以病人安全風險管理為中心（上），月旦醫事法報告，2018年6月第20期，頁144-168）.}
• ^{Liang, C. ＆ Liu, H., A comparative analysis of the roles and functions of hospital legal departments in Taiwan and the US, 54 Tunghai Uni. L. J. 99-148（2018）（梁志鳴、劉汗曦，醫法互動最前線：台美醫療機構法務部門之實證比較分析，東海大學法學研究，2018年4月第54期，頁99-148）.}
• ^{Liang, C. & Chang, C., The Weakening Judicial Review of Administrative Power in Taiwan: The Regulation of Dishonest Drug Price Reporting under the National Health Insurance as a Case Study, 47 Nat. Taiwan Uni. L. J. 491-561（2018）（梁志鳴、張兆恬，我國全民健保藥價不實申報管制架構初探：兼論管制國家司法監督角色的弱化，2018年3月第47卷2期，頁491-561）.}
• ^{Liang, C., Admission of Expert Testimony in American Courts: From Frye to Daubert, 216 Formosa Trans. L. Rev. 1-13（2017）（梁志鳴，美國法院採用專家證言之審查標準：從Frye 到Daubert 原則的歷史演進，萬國法律，2017年12月第216期，頁1-13）.}
• ^{Liang, C., Truth, Expert Review of Medical Disputes, and the Future of Medical Malpractice Dispute Resolution: Gearing towards an Early Liability Assessment Scheme, 2 Taiwan Health L. Report 173（2016）（梁志鳴，真相、鑑定與醫療糾紛處理的未來：走向事故責任的早期評估，月旦醫事法報告，2016年10月第2期，頁173-180）.}
• ^{Sheridan, D. & Liang, C., The “So What” Question of Taiwan Studies: The Changing Academic Market of North America and the Future Development of NATSA, in Crossing Disciplines and Generations: 20 Years of NATSA 183（2016）（謝力登、梁志鳴，對台灣研究 “So What” 問題的深思：從北美學術市場結構反省NATSA 發展策略 （2012-2014），收錄於《跨界跨代的台灣研究：北美台灣研究學會（NATSA）二十年》，巨流出版社，2016年7月，頁183-205）.}
• ^{Liang, C., The Regulatory Approach to Workplace Violence in Healthcare, 206 Formosa Trans. L. Rev. 19（2016）（梁志鳴，醫療暴力風險行政管制策略分析，萬國法律，2016年4月第206期，頁19-38）.}

English

• ^{Liang, C., Leflar, R., and Wu, C., Taiwan's Medical Injury Law in Action, 38(1) Emory Int’l L. Rev. 1 (2024).}
• ^{Tsai, J.., Shih, T., Tsai, T., Lee, S., and Liang, C., Individualism, economic development, and democracy as determinants of COVID-19 risk information on 132 government websites, 34 Preventive Med. Rep. 1 (2023) (corresponding author).}
• ^{Liang, C, Rethinking the Tort Liability System and Patient Safety: From the Conventional Wisdom to Learning from Litigation, 12(1) Indiana Health L. Rev. 327 (2015).}
• ^{Trubek, L.G., Oliver, T.R., Liang, C, Mokrohisky, M., and Campbell, T., Improving Cancer Outcomes through Strong Networks and Regulatory Frameworks: Lessons from the United States and the European Union, 14(1) J. Health Care L. & Pol’y 119 (2011).}